Each challenge tests 8 biotech competitors per tissue (A-H) across 5 patient tissues for statistical significance. Success is ≥50% improvement in functional response score vs. control. We aim for ~40 participants per challenge, running phased batches. 

 We use CURESPONSE’s clinically validated, CE-marked ex-vivo system, which preserves full human tumor dynamics with high accuracy — far beyond traditional models.

• Zero upfront cost — commit via milestone rewards.
• $1M to FUSIONx per successful match; $1M (or equivalent) to the winning biotech, plus option rights or exclusive negotiation.
• Elevate assets, extend product life, improve response rates, and access external innovation risk-free.

• $10K entry (testing on 5 tissues; discounts for multiples).
• Visibility to pharma, objective human-based validation, and clear rewards.
• Huge upside: $400K prize on success, plus partnership options (see below).
• Strategic perks: Direct BD opportunities, data-driven proof for fundraising.

You choose your path:

• Prize + Partnership: $400K cash prize plus collaborate with FUSIONx on the combo asset (45% your company / 55% FUSIONx, reflecting our platform role and deadlock avoidance). The prize is awarded upon signing a simple partnership agreement.
• Full Ownership: Retain 100% IP/ownership of the combo — no prize, but a modest milestone/royalty (5–10%) to FUSIONx for enabling the discovery. This ensures mutual commitment while giving you flexibility.

You get free additional testing on 5 more tissues (your choice: combo or standalone) to refine and potentially qualify.